DexCom’s presentations at the recent American Diabetes Association conference centered on the COACH study, which was looking at the clinical efficacy of its G5 and G6 continuous glucose monitors (CGMs).
The 519-patient study required patients to self-administer insulin based on self-monitored blood glucose levels for six months. After this, patients switched to CGMs for six months. The study’s primary outcome was a reduction in hypoglycemic events that required medical care